Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel technology to monitor ’hidden depths’ of silent killer

02.10.2003


New studies, ASTEROID and ORION, combine CRESTOR™ with cutting-edge imaging techniques, to be at the forefront of the fight against atherosclerosis



Details of two new studies announced by AstraZeneca at the XIIIth International Symposium on Atherosclerosis (ISA) could provide the clearest picture yet of the effects of statins on atherosclerosis, the main cause of coronary artery disease.

Each study is combining the highly effective statin CRESTOR (rosuvastatin) with cutting-edge imaging technology: intravascular ultrasound (IVUS)1 or magnetic resonance imaging (MRI)2,3; to evaluate whether CRESTOR can slow the progression or even lead to a regression of atherosclerosis.


Atherosclerosis gradually narrows the blood vessels, which can lead to a reduction in blood supply to vital organs such as the brain and heart, in some cases this can lead to angina and even a stroke or heart attack. A number of studies have shown that statins may slow the progression or even cause regression of atherosclerosis.4-7 Lowering LDL-cholesterol (LDL-C) slows the progression of atherosclerosis, however, it has been suggested that a larger reduction of at least 40% in LDL-C is needed to observe a regression of atherosclerosis.8,9

Treatment of atherosclerosis should be considered an important target as clinical studies have shown that <1% regression of coronary atherosclerosis is associated with major (70-80%) reductions in clinical events such as heart attacks.10

"Patients with atherosclerosis can show no symptoms for years before experiencing a serious, sometimes fatal, cardiovascular event – often making this disease a silent killer," explained Professor Gunnar Olsson, Vice President and Head of Cardiovascular Therapy Area, AstraZeneca.

"We know that raised LDL-C (or bad cholesterol) and low levels of HDL-C (or good cholesterol) are major risk factors for atherosclerosis and coronary heart disease. CRESTOR can reduce LDL-cholesterol significantly more than the same and some higher doses of other widely used statins and also provides the added benefit of raising HDL-cholesterol or good cholesterol. The three ongoing studies, ASTEROID, ORION and METEOR will demonstrate the benefits of CRESTOR on the atherosclerotic disease process thereby offering the potential for improving the prognosis of patients with, or at risk of, cardiovascular disease – the world’s number one killer."

ASTEROID1 and ORION2, 3, 11 are the first studies to evaluate CRESTOR 40mg – which has been shown to reduce LDL-C by up to 63%12 – on atherosclerosis using the novel imaging technologies IVUS and MRI.

Dr. Steven Nissen, Medical Director of the Cardiovascular Coordinating Center at the Cleveland Clinic Foundation, USA, is the principal investigator on the ASTEROID study. He commented: "Current imaging technology, such as coronary angiography, has only allowed us to visualise the narrowing of the blood vessel caused by atherosclerosis. IVUS lets us see the equally dangerous atherosclerosis hidden within the vessel wall. We are visualising not just the tip of the iceberg, but also what is below the waterline. CRESTOR, compared to other statins, provides outstanding efficacy both in terms of reducing LDL-C (bad cholesterol) and raising HDL-C (good cholesterol). ASTEROID will determine if a maximum dose (40mg) of this particular agent can actually reduce the burden of coronary atherosclerosis during two years of treatment."

"By using non-invasive MRI in ORION we will be able to measure the exact shape, size and distribution of atherosclerosis in blood vessels which may enable us to better evaluate the vascular effects of lipid-lowering therapy, and in clinical practice the use of MRI could facilitate early diagnosis and treatment," stated Dr. Baocheng Chu of the University of Washington School of Medicine, Seattle and investigator for ORION. He continued, "ORION will also show the benefits of CRESTOR in hypercholesterolaemic patients with established atherosclerotic disease."

ASTEROID, which started in November 2002, will recruit 450 patients with coronary artery disease from approximately 60 centres worldwide who will be treated with CRESTOR 40mg once daily for 24 months. The study will measure the percentage change in coronary artery volume at the end of treatment using IVUS. Coronary atherosclerosis will also be assessed using quantitative coronary angiography. 1

ORION has completed recruitment and 39 hypercholesterolaemic patients with established atherosclerosis have been randomised to receive CRESTOR 5mg or 40mg for 24 months. Baseline measurements from patients enrolled in the study were announced at ISA. The change in bilateral carotid artery wall volume will be measured by using MRI. Changes in the intima media thickness of the carotid arteries will also be measured using B-mode ultrasound. 2, 3, 11

METEOR is the third study within the GALAXY Programme evaluating the effects of CRESTOR on atherosclerosis.13 The study which started in August 2002 is using B-mode ultrasound to compare the effects of CRESTOR 40mg or placebo on intima media thickness of the carotid arteries in 840 asymptomatic patients with sub-clinical atherosclerosis who are not routinely treated with statin medication.

CRESTOR has now received regulatory approvals across three continents; America, including the USA, Europe and Asia, and has been launched in several countries worldwide. CRESTOR is awaiting approval in a number of other countries over the coming months.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

AstraZeneca has more than 40 years experience in cardiovascular medicine and aims to increase lifespan and improve quality of life by reducing the risk, prevalence and impact of cardiovascular disease. AstraZeneca has a comprehensive cardiovascular portfolio including CRESTORTM, ATACANDTM, ZESTRILTM, TENORMINTM, SELOKEN ZOK /TOPROL-XLTM and PLENDILTM. This heritage is complemented by an innovative pipeline including the first oral direct thrombin inhibitor, EXANTATM, and a novel treatment for type 2 diabetes / metabolic syndrome, GALIDATM.



For further information please visit: http://www.AstraZenecaPressOffice.com.

Contact:
Julia Walker, Global PR Manager, Cardiovascular Therapy Area, AstraZeneca
Tel: 44-0-1625-510866
Mobile (in Japan): 81-0-90-5340-2294
Mobile: 44-0-7718-80-1984
Email: julia.walker@astrazeneca.com

Ellie Goss or Stephanie Martin, Shire Health International
Tel: 44-0-20-7471-1500
Ellie Goss’s mobile (in Japan): 81-0-90-5340-4799
Email: .goss@shirehealthinternational.com

Stephanie Martin | EurekAlert!
Further information:
http://www.tshg.com/
http://www.AstraZenecaPressOffice.com

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>